

FOI REF: 26/392

3rd July 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I am analysing the treatment of lung cancer and would greatly appreciate it if you could answer the following question:

1. How many non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

• ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)	32
• Amivantamab Monotherapy	0
• Atezolizumab monotherapy (any formulation) OR Atezolizumab monotherapy (infusion only)	2
• Atezolizumab (any formulation) + Bevacizumab + Carboplatin + Paclitaxel	0
• Atezolizumab monotherapy (subcutaneous injection only)	7
• Dabrafenib + Trametinib	0
• Docetaxel monotherapy or in combination with Carboplatin/Cisplatin	0
• Durvalumab	2
• Gemcitabine	0
• Nintedanib + Docetaxel	4
• Nivolumab	0
• Osimertinib	29
• Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)	0
• Paclitaxel	0
• Pembrolizumab Monotherapy	18
• Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)	6
• Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)	6
• Pemetrexed + Platinum (Carboplatin/Cisplatin)	10
• RET Inhibitors (Pralsetinib, Selpercatinib)	0
• Sotorasib	2
• Tepotinib	2
• Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin	1
• Other active systemic anti-cancer therapy	23

• Palliative care only	Section 12(1) applied, please see below
• Amivantamab with carboplatin and pemetrexed	0
• Cemiplimab with platinum-based chemotherapy	0
• Adagrasib	0
• Datopotamab deruxtecan	0
• Amivantamab with lazertinib	0
• Pembrolizumab subcutaneous injection	0

East Sussex Healthcare NHS Trust does not centrally record patients being treated for palliative care only. To enable the Trust to provide this information will require a manual review of patients' notes to establish if we hold this information, and discussing each patient with individual clinicians, which we estimate would take in excess of 18 hours. We are therefore applying Section 12(1) to this part of your request.

Section 12(1) of the Act allows a public authority to refuse to comply with a request for information if the authority estimates that the cost of compliance would exceed the 'appropriate limit', as defined by the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004 (the Regulations). These state that this cost limit is £450 for public authorities which are not part of central government or the armed forces. The costs are calculated at £25 per hour per person regardless of the rate of pay, which means that the limit will be exceeded if the work involved would exceed 18 hours. The Trust estimates that the cost of complying with this request would significantly exceed the above limit.

2. Does your trust participate in any clinical trials for Non-Small Cell Lung Cancer? If so, please provide the name of each trial, and the number of patients taking part.

East Sussex Healthcare NHS Trust currently has 3 clinical trials open for Non-Small Cell Lung Cancer, details as follows:

IRAS Number	Trial Name	Number of Participants recruited
IRAS 1004165	REFINE Lung: A randomised open-label phase III trial of Reduced Frequency pembrolizumab immuNothErapy for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) utilising a novel multi-arm frequency-response optimisation design.	1
IRAS 1012232	DS8201-793 (DESTINY-Lung06) A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination with Pembrolizumab, as First-line Therapy in Participants with Locally Advanced Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)	No recruitments to date
IRAS: 361412	LEPIDOPTERA -Prospective, Multi-country, Observational Study of Clinical Outcomes in EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Approved Amivantamab-containing Regimens Under Standard Clinical Practice	No patients recruited as yet due to NICE guidance for Standards of Care (SOC) for medication

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
 East Sussex Healthcare NHS Trust
 0300 131 4716
 Core Hours of Business: Monday to Friday 9.00am to 4.00pm